Back to Journals » Neuropsychiatric Disease and Treatment » Volume 13

Risperidone improves interpersonal perception and executive function in patients with schizophrenia

Authors Zhou Z, Zhu Y, Wang J, Zhu H

Received 27 August 2016

Accepted for publication 27 October 2016

Published 28 December 2016 Volume 2017:13 Pages 101—107

DOI https://doi.org/10.2147/NDT.S120843

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 4

Editor who approved publication: Professor Wai Kwong Tang


Zhenhe Zhou, Yuanyuan Zhu, Jun Wang, Hongmei Zhu

Department of Psychiatry, Wuxi Mental Health Center of Nanjing Medical University, Jiangsu Province, People’s Republic of China

Objective: To investigate whether risperidone improves social cognitive impairments and executive dysfunction in people with schizophrenia.
Methods: Fifty-six patients who met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, diagnostic criteria for schizophrenia were allocated to a risperidone treatment group (RTG, n=28) and a typical antipsychotic treatment group (TATG, n=28). Twenty-eight healthy volunteers were recruited as the normal control group (NCG). The Positive and Negative Syndrome Scale, Interpersonal Perception Task-15 (IPT-15), and Wisconsin Card Sorting Test (WCST) were rated at baseline and after 4 and 12 weeks of treatment with risperidone or typical antipsychotics.
Results: Risperidone and typical antipsychotics decreased Positive and Negative Syndrome Scale scores for total psychopathology and positive and negative symptoms. At baseline, in the IPT-15, total scores and five factor scores, as well as the number of categories completed and the percentage of conceptual level responses, were significantly lower in the RTG and TATG than in the NCG, whereas total response errors, perseverative errors, and failure to maintain set were significantly higher in the patient groups than in the NCG. Repeated measures analysis of variance revealed a significant main effect of time period (baseline, 4 weeks, and 12 weeks) for IPT-15 scores and WCST performances, and significant interactions for time period × group (RTG and TATG). Multivariate analysis of variance showed no significant differences between the RTG and TATG on IPT-15 scores at 4 weeks, but there were significant differences between these two groups at 12 weeks. Significant differences were also found between the RTG and TATG on WCST performances at 4 and 12 weeks.
Conclusion: Individuals with schizophrenia have impairments in social cognitive and executive function, which might be improved by risperidone.

Keywords: schizophrenia, executive function, social cognition, Interpersonal Perception Task-15, Wisconsin Card Sorting Test

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]